CD3AK细胞冻融提取液的抗肿瘤活性研究

为研究ＣＤ３ＡＫ细胞冻融提取液的抗肿瘤作用，作者采集正常人外周血分离单个核细胞（ＰＢＭＣ），先用抗ＣＤ３的单克隆抗体（ＣＤ３ＭｃＡｂ）的ｒＩＬ－２诱导和激活，使之成为ＣＤ３ＭｃＡｂ激活的杀伤细胞（ＣＤ３ＡＫ），再制备ＣＤ３ＡＫ的冻融提取液，然后进行体内，外抗肿瘤实验。结果；低剂量的ＣＤ３ＭｃＡｂ和ｒＩＬ－２能明显诱导ＰＢＭＣ的活化和增殖；激活后的ＣＤ３ＡＫ细胞冻融提取液可抑制小鼠肝癌实体瘤细胞Ｈ２

Antitumor activity of the lysates prepared from anti-CD3 antibody activated killer cells]

This study was directed at the antitumor activity of the lysates prepared from CD3McAb activated killer cells. We separated the peripheral blood monocytes(PBMC) from normal adults. The PBMC were induced by monoclonal antibody specific for CD3(CD3McAb) and activated by rIL-2. The CD3McAb-activated killer cells (CD3AK) were smashed by ultrasonic wave, along with frozen and thawed three times, then the lysates were obtained by centrifugation. The lysates were tested for antitumor activity in vivo and in vitro. The results revealed that the inhibition rate of the lysates that acted on mice solid tumor hepatoma 22(H22) was 68.20% and the killing activity of the lysates on K562 and Raji were 83.32%, and 66.83% respectively. The results of this experiment suggested that the lysates prepared from CD3McAb-activated killer cells is one of probable agents that might apply to biotherapy for tumors.